Albumin (as Excipient) Market Research Report – Global Forecast till 2027

Albumin (as Excipient) Market Research Report: By Type (Human, Bovine, and Recombinant Serum Albumin), Application (Drug Formulation, Drug Delivery, Vaccines, Medical Device Coating, Diagnostics, and Others), End User – Global Forecast Till 2027

ID: MRFR/HC/5973-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Global albumin (as excipient) market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 736 million in 2017 and is projected to grow at a CAGR of 6.1% over the forecast period.


The choice of excipient is an important factor in the formulation of pharmaceuticals. Albumin as excipient in formulation has been reported to improve lyophilized cake formation, dissolving properties of API from lyophilized powder, and solubility.


Rising adoption of recombinant albumin-based drug delivery systems by pharmaceutical and biotechnology companies is one of the key factors driving the albumin (as excipient) market. For instance, in 2014, Novozymes Biopharma DK A/S announced that its albumin-based VELTIS technology is used by GlaxoSmithKline plc in the manufacturing of type II diabetes drug (Tanzeum and Eperzan) in Europe.


Various other factors such as increasing prevalence of chronic conditions, technological advancements, emerging markets in APAC and RoW, rising awareness about albumin as excipient, and increase in usage of albumin for non-therapeutic applications are also expected to propel the growth of the market.


However, the adverse reactions associated with albumin, rising shift toward serum-free solutions, and unfavourable reimbursement policies can hamper the market growth over the forecast period.


Key Players


Some of the key players in the global albumin (as excipient) market are Albumedix A/S, Albumin Therapeutics, LLC, Baxalta Incorporated, Baxter International Inc., Biotest AG, CSL Behring LLC, Celgene, China Biologic Products, Inc., Grifols International, S.A, HiMedia Laboratories Pvt. Ltd., InVitria, Medxbio Pte Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA), and others.


Intended Audience



  • Government and Private Laboratories

  • Research and Development (R&D) companies

  • Biotechnology Laboratories

  • Market Research and Consulting Service Providers


Market Segmentation


The global albumin (as excipient) market is segmented based on type, application, end user, and region.


The global market for albumin (as excipient), by type is segmented into human serum albumin, bovine serum albumin, and recombinant albumin. The human serum albumin segment is anticipated to hold the largest market share owing to the increasing cases of chronic conditions such as, cardiac disorders, infectious diseases, and others.


Based on application, the market is segmented into drug formulation, drug delivery, vaccines, medical device coating, culture media & stabilizers, diagnostics, in vitro fertilization, and others.


Based on end user, the market is segmented into pharmaceutical & biotechnology industry, academic and research institutes, and others.


In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.


The albumin (as excipient) market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European albumin (as excipient) market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The albumin (as excipient) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The albumin (as excipient) market in the Middle East & Africa has been segmented into the Middle East and Africa.


Global Albumin (as Excipient) Market Share (%), by Region, 2017


Albumin (as Excipient) Market


Sources: MRFR Analysis


Regional Market Summary


The Americas dominated the global market for albumin (as excipient) owing to the rising R&D investments and increasing prevalence of diabetes within the region. According to the 2015 data suggested by the Centres for Disease Control and Prevention (CDC), around 30.3 million Americans were suffering from diabetes.


In 2017, it was estimated that Europe stood second in the global Albumin (as Excipient) market. This can be attributed to the increasing technological advancements, and rising participation of market players. For instance, in 2016, a Denmark based company, Novozymes launched its recombinant albumin business as a new independent called Albumedix.


Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. As per the data suggested by the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion.


On the other hand, the Middle East and Africa held least share in the global albumin (as excipient) market due to inadequate economic development, especially within the African region.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the Albumin (as Excipient). It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.


Market Segmentation and Key Market Players


Global Albumin (as Excipient) Market, by Type



  • Human Serum Albumin

  • Bovine Serum Albumin

  • Recombinant Albumin


Global Albumin (as Excipient) Market, by Application



  • Drug Formulation

  • Drug Delivery

  • Vaccines

  • Medical Device Coating

  • Culture Media & Stabilizers

  • Diagnostics

  • In Vitro Fertilization

  • Others


Global Albumin (as Excipient) Market, by End User



  • Pharmaceutical & Biotechnology Industry

  • Academic and Research Institutes

  • Others



Frequently Asked Questions (FAQ) :


The global albumin market was valued at USD 736 million in 2017.

The global albumin market is expected to exhibit a strong 6.1% CAGR over the forecast period from 2018 to 2023.

The increasing use of recombinant albumin in drug delivery systems is likely to be the major driver for the albumin market over the forecast period.

The risk of adverse reactions to albumin and the rising demand for serum-free solutions are the key restraints on the global albumin market.

Leading players in the albumin market include Albumedix A/S, Baxalta Inc., Baxter, CSL Behring LLC, China Biologic Products Inc., Grifols, InVitria, and Mitsubishi Tanabe Pharma Corporation, among others.

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

5.4 Pricing Analysis

Chapter 6. Global Albumin (as Excipient) Market, by Type

6.1 Introduction

6.2 Human Serum Albumin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Bovine Serum Albumin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Recombinant Albumin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Albumin (as Excipient) Market, by Application

7.1 Introduction

7.2 Drug Formulation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Drug Delivery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Vaccines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Medical Device Coating

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Culture Media & Stabilizers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Diagnostics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8 In Vitro Fertilization

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Albumin (as Excipient) Market, by End User

7.1 Introduction

7.2 Pharmaceutical & Biotechnology Industry

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Academic and Research Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Albumin (as Excipient) Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 U.S.

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9. Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 Albumedix A/S (Novozyme A/S)

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Biotest AG

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 China Biologic Products Holdings, Inc.

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 CSL Behring LLC

10.4.1 Company Overview

10.4.2 Product Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Albumin Therapeutics, LLC

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Baxalta Incorporated

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Baxter International Inc.

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Celgene

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 Grifols International, S.A

10.9.1 Overview

10.9.2 Product Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Octapharma AG

10.10.1 Overview

10.10.2 Product Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.11 HiMedia Laboratories Pvt. Ltd.

10.11.1 Overview

10.11.2 Product Overview

10.11.3 Financials

10.11.4 Key Developments

10.11.5 SWOT Analysis

10.12 InVitria

10.12.1 Overview

10.12.2 Product Overview

10.12.3 Financials

10.12.4 Key Developments

10.12.5 SWOT Analysis

10.13 Medxbio Pte Ltd.

10.13.1 Overview

10.13.2 Product Overview

10.13.3 Financials

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.14 Mitsubishi Tanabe Pharma Corporation

10.14.1 Overview

10.14.2 Product Overview

10.14.3 Financials

10.14.4 Key Developments

10.14.5 SWOT Analysis

10.15 RayBiotech, Inc.

10.15.1 Overview

10.15.2 Product Overview

10.15.3 Financials

10.15.4 Key Developments

10.15.5 SWOT Analysis

10.16 SeraCare Life Sciences

10.16.1 Overview

10.16.2 Product Overview

10.16.3 Financials

10.16.4 Key Developments

10.16.6 SWOT Analysis

10.17 Sigma-Aldrich Co. (Merck KGaA)

10.17.1 Overview

10.17.2 Product Overview

10.17.3 Financials

10.17.4 Key Developments

10.17.7 SWOT Analysis

10.18 Others

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictionsfor the global albumin (as excipient) market

Chapter 12 Appendix

LIST OF TABLES

Table 1 Albumin (as Excipient) Market Synopsis, 2020-2027

Table 2 Albumin (as Excipient) Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Albumin (as Excipient) Market, by Region, 2020-2027 (USD Million)

Table 4 Global Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 5 Global Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 6 Global Albumin (as Excipient) Market, End User, 2020-2027 (USD Million)

Table 7 North America: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 8 North America: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 9 North America: Albumin (as Excipient) Market, End User, 2020-2027 (USDMillion)

Table 10 US: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 11 US: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 12 US: Albumin (as Excipient) Market, End User, 2020-2027 (USD Million)

Table 13 Canada:Albumin (as Excipient) Market,by Type, 2020-2027 (USD Million)

Table 14 Canada: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 15 Canada: Albumin (as Excipient) Market, End User, 2020-2027 (USDMillion)

Table 16 South America: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 17 South America: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 18 South America: Albumin (as Excipient) Market, End User, 2020-2027 (USDMillion)

Table 19 Europe: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 20 Europe: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 21 Europe: Albumin (as Excipient) Market, End User, 2020-2027 (USD Million)

Table 22 Western Europe: Albumin (as Excipient) Market, by Type, 2020-2027 (USDMillion)

Table 23 Western Europe: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 24 Western Europe: Albumin (as Excipient) Market, by End User, 2020-2027(USD Million)

Table 25 Eastern Europe: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 26 Eastern Europe: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 27 Eastern Europe: Albumin (as Excipient) Market, End User, 2020-2027(USD Million)

Table 28 Asia-Pacific: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 29 Asia-Pacific: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 30 Asia-Pacific: Albumin (as Excipient) Market, End User, 2020-2027 (USD Million)

Table 31 Middle East & Africa: Albumin (as Excipient) Market, by Type, 2020-2027 (USD Million)

Table 32 Middle East & Africa: Albumin (as Excipient) Market, by Application, 2020-2027 (USD Million)

Table 33 Middle East & Africa: Albumin (as Excipient) Market, End User, 2020-2027(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Albumin (as Excipient) Market

Figure 3 Market Dynamics for Global Albumin (as Excipient) Market

Figure 4 Albumin (as Excipient) Market Share, by Type, 2020

Figure 5 Albumin (as Excipient) Market Share, by Application, 2020

Figure 6 Albumin (as Excipient) Market Share, End User, 2020

Figure 7 Albumin (as Excipient) Market Share, by Region, 2020

Figure 8 North America: Albumin (as Excipient) Market Share, by Country, 2020

Figure 9 Europe: Albumin (as Excipient) Market Share, by Country, 2020

Figure 10 Asia-Pacific: Albumin (as Excipient) Market Share, by Country, 2020

Figure 11 Middle East & Africa: Albumin (as Excipient) Market Share, by Region, 2020

Figure 12 Albumin (as Excipient) Market: Company Share Analysis, 2020 (%)

Figure 13 Albumedix A/S (Novozyme A/S): Key Financials

Figure 14 Albumedix A/S (Novozyme A/S): Segmental Revenue

Figure 15 Albumedix A/S (Novozyme A/S): Geographical Revenue

Figure 16 Biotest AG: Key Financials

Figure 17 Biotest AG: Segmental Revenue

Figure 18 Biotest AG: Geographical Revenue

Figure 19 China Biologic Products Holdings, Inc.: Key Financials

Figure 20 China Biologic Products Holdings, Inc.: Segmental Revenue

Figure 21 China Biologic Products Holdings, Inc.: Geographical Revenue

Figure 22 CSL Behring LLC: Key Financials

Figure 23 CSL Behring LLC: Segmental Revenue

Figure 24 CSL Behring LLC: Geographical Revenue

Figure 25 Albumin Therapeutics, LLC: Key Financials

Figure 26 Albumin Therapeutics, LLC: Segmental Revenue

Figure 27 Albumin Therapeutics, LLC: Geographical Revenue

Figure 28 Baxalta Incorporated: Key Financials

Figure 29 Baxalta Incorporated: Segmental Revenue

Figure 30 Baxalta Incorporated: Geographical Revenue

Figure 31 Baxter International Inc.: Key Financials

Figure 32 Baxter International Inc.: Segmental Revenue

Figure 33 Baxter International Inc.: Geographical Revenue

Figure 34 Mitsubishi Tanabe Pharma Corporation: Key Financials

Figure 35 Mitsubishi Tanabe Pharma Corporation: Segmental Revenue

Figure 36 Mitsubishi Tanabe Pharma Corporation: Geographical Revenue

Figure 37 Celgene: Key Financials

Figure 38 Celgene: Segmental Revenue

Figure 39 Celgene: Geographical Revenue

Figure 40 Grifols International, S.A: Key Financials

Figure 41 Grifols International, S.A: Segmental Revenue

Figure 42 Grifols International, S.A: Geographical Revenue

Figure 43 Octapharma AG: Key Financials

Figure 44 Octapharma AG:Segmental Revenue

Figure 45 Octapharma AG: Geographical Revenue

Figure 46 HiMedia Laboratories Pvt. Ltd.: Key Financials

Figure 47 HiMedia Laboratories Pvt. Ltd.: Segmental Revenue

Figure 48 HiMedia Laboratories Pvt. Ltd.: Geographical Revenue

Figure 49 InVitria: Key Financials

Figure 50 InVitria: Segmental Revenue

Figure 51 InVitria: Geographical Revenue

Figure 52 Medxbio Pte Ltd.: Key Financials

Figure 53 Medxbio Pte Ltd.: Segmental Revenue

Figure 54 Medxbio Pte Ltd.: Geographical Revenue

Figure 55 SeraCare Life Sciences: Key Financials

Figure 56 SeraCare Life Sciences: Segmental Revenue

Figure 57 SeraCare Life Sciences: Geographical Revenue

Figure 58 Sigma-Aldrich Co. (Merck KGaA): Key Financials

Figure 59 Sigma-Aldrich Co. (Merck KGaA): Segmental Revenue

Figure 60 Sigma-Aldrich Co. (Merck KGaA): Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.